Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 3 Cancer Trials

Research area

Phase 3 Breast Cancer trials

You will find only Phase 3 breast cancer studies on this site, and that includes combined Phase 2/3. If you are wondering whether a study could suit you, Phase 3 Cancer Trials is here to help you work that out.

Updated

Call (888) 306-7888
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Phase 3 breast cancer studies in numbers

Phase 3 breast cancer studies recruiting in the U.S.
60
states with a study site
51

Source: ClinicalTrials.gov. Data processed .

Find Phase 3 breast cancer studies by state

These states have the most studies recruiting right now.

Phase 3 breast cancer studies recruiting now

As of November 18, 2026, 60 Phase 3 breast cancer studies are recruiting participants in the United States, according to ClinicalTrials.gov. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry. This is what they have in common.

What they test

  • medications45
  • biologics such as vaccines or antibodies12
  • other approaches12
  • procedures9
  • radiation7

A study can test more than one.

Main purpose

  • treating a condition52
  • supportive care4
  • prevention2
  • diagnosis1

Phase

  • Phase 2/34
  • Phase 356

Who runs them

  • industry33
  • university, hospital or other25
  • government2

Who they enroll

  • adults (18 to 64)59
  • older adults (65 and over)57

These counts come from each study's public record and change as studies open and close. Browse every location to see what is recruiting near you.

Source: ClinicalTrials.gov. Data processed . Each bar shows a count as a share of all 60 studies.

Recently updated Phase 3 breast cancer studies

The 6 studies whose public records changed most recently, with some of the places each is recruiting. Select a study to read its full record on ClinicalTrials.gov.

  1. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Abilene, TX · Albuquerque, NM · Alexandria, LA · and 69 more U.S. locations
    Registry record
    NCT06393374 · updated
  2. Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Aberdeen, MD · Albuquerque, NM · Ames, IA · and 213 more U.S. locations
    Registry record
    NCT07391774 · updated
  3. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Albuquerque, NM · Altamonte Springs, FL · Athens, GA · and 30 more U.S. locations
    Registry record
    NCT06841354 · updated
  4. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Altamonte Springs, FL · Baltimore, MD · Boston, MA · and 53 more U.S. locations
    Registry record
    NCT06966700 · updated
  5. Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    University of Utah
    Recruiting in
    Salt Lake City, UT
    Registry record
    NCT07166042 · updated
  6. T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Daiichi Sankyo
    Recruiting in
    Columbia, MD · El Paso, TX · Fairfax, VA · and 3 more U.S. locations
    Registry record
    NCT07683754 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in the United States on ClinicalTrials.gov.

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and some of the places it is recruiting) exactly as registered. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.

Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

What Phase 3 breast cancer studies look at

The breast cancer studies on this site are all in Phase 3, and combined Phase 2/3 counts too. Each one is built around a single, specific question. So the tasks asked of you in one study may not match those in another.

In every study, the thing under test is investigational. That word means the answers are not in yet. Research teams are still learning how well it works and what its risks are. That is the reason the study exists.

Who may be able to take part

Requirements are different for every study. They can include your age, your health history, the medications you take now, and how breast cancer affects you. Some studies also enroll people who do not have the condition.

You are not expected to work out eligibility on your own. The study team checks it at a screening visit. See how eligibility and screening work.

What taking part usually involves

  1. A first conversation

    Nothing else happens until a coordinator has talked with you. They describe the Phase 3 breast cancer study in broad terms. Then they answer whatever you want to ask.

  2. Informed consent

    You receive everything about the Phase 3 trial in writing from the study team. That document sets out the risks known so far. Saying yes or no is entirely up to you.

  3. Screening

    Screening checks whether this study is suitable for you. It uses questions about your health along with tests. Being screened does not mean you will take part, and not everyone does.

  4. Study visits

    Joining a Phase 3 breast cancer trial means coming in for scheduled visits. At each one, the team follows how your health is doing. Leaving the study is open to you at any point.

Questions about Phase 3 breast cancer studies

Do I need a diagnosis to join a study about breast cancer?

That varies from one study to another. Certain studies ask that your diagnosis be confirmed. Others assess you as part of screening instead. Which one applies is something the study team will tell you.

Would I have to change the care I receive now?

It depends on the particular Phase 3 trial. Some let your current care continue, and others do not. Either way, please change nothing on your own. The study doctor goes over this point with you. Before deciding, you are welcome to talk it through with your own doctor as well.

Is there a cost to take part?

As a participant, you are generally not charged for the study medication, study tests, or study visits. Our guide explains costs in more detail.

Ask about Phase 3 breast cancer studies

A coordinator will reach out once you have told us a little about yourself. Making an enquiry is only a question. It leaves you free of any commitment.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Independent information

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 306-7888

or send a short form

How should we reach you?

Call